ADMA Biologics ADMA Warrants Issued In Connection With Notes Payable
Warrants Issued In Connection With Notes Payable at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:WarrantsIssuedInConnectionWithNotesPayable.
The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's warrants issued in connection with notes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's warrants issued in connection with notes payable?
- ADMA Biologics (ADMA) reported warrants issued in connection with notes payable of $0 in Q4 2025.
- What is the long-term trend for ADMA Biologics's warrants issued in connection with notes payable?
- Over 2 years (2023 to 2025), ADMA Biologics's warrants issued in connection with notes payable has grown at a -100.0% compound annual growth rate (CAGR), from $5.6M to $0.
- What does warrants issued in connection with notes payable mean?
- This metric quantifies the value or impact of equity warrants granted to lenders as a component of debt financing arrangements. It serves as a form of 'equity kicker' used to incentivize debt providers, often indicating the cost of capital beyond stated interest rates. Investors track this to assess potential future dilution of existing shareholders and the company's reliance on equity-linked instruments to secure financing.